SCH-23390
SCH-23390 is a dopamine D1-like receptor antagonist (with Ki values of 0.2 nM and 0.3 nM for the D1 and D5 receptor subtypes, respectively). SCH-23390 can shorten the latency period for cocaine-induced lever pressing behavior in rats. SCH-23390 can also eliminate generalized seizures caused by chemical convulsants, such as arecoline and strychnine, and is used in research on neurological disorders related to the dopamine system[1][2].
Product Specifications
CAS Number
87075-17-0
Product Name Alternative
R- (+) -SCH-23390
UNSPSC
12352005
Target
Dopamine Receptor
Related Pathways
GPCR/G Protein; Neuronal Signaling
Field of Research
Neurological Disease
Smiles
OC1=C(Cl)C=C2CCN(C)C[C@H](C3=CC=CC=C3)C2=C1
Molecular Formula
C17H18ClNO
Molecular Weight
287.78
References & Citations
[1]Dakota B Zinani, et al. SCH23390 and a humanized anti-cocaine mAb decrease the latency to cocaine-induced reinstatement of lever pressing behavior in rats that self-administer cocaine. Sci Rep. 2023 Sep 4;13 (1) :14566.|[2]J A Bourne, et al. SCH 23390: the first selective dopamine D1-like receptor antagonist.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Citation 01
Mol Brain. 2025 Jul 16;18 (1) :63.|Acta Pharmacol Sin. 2020 Feb;41 (2) :173-180.|Acta Pharmacol Sin. 2024 Aug;45 (8) :1582-1590.|Adv Sci (Weinh) . 2025 Sep;12 (33) :e02276.|Aquaculture. 2025 Apr 15.|Behav Pharmacol. 2024 Jun 1;35 (4) :193-200.|Biochem Biophys Res Commun. 2022 Jan 15:588:83-89.|Biochem Biophys Res Commun. 2022 Nov 12:629:183-188.|Biochem Pharmacol. 2025 Nov 29:244:117576.|bioRxiv. 2024 Dec 23:2024.12.22.629999.|Brain Res Bull. 2021 Oct:175:136-149.|Cell Rep. 2024 Sep 10;43 (9) :114717.|Eur J Pharmacol. 2024 Jul 30:176866.|Food Biosci. 2025 Oct.|Insect Biochem Mol Biol. 2025 May:180:104312.|Int Immunopharmacol. 2020 Nov;88:106963.|Int J Biol Macromol. 2023 Aug 30:247:125703.|J Hazard Mater. 2025 Aug 5:496:139466.|J Neurosci. 2024 Jul 17:e0740242024.|J Neurosci. 2025 Sep 3;45 (36) :e0382252025.|J Psychiatry Neurosci. 2024 Feb 1;49 (1) :E23-E34.|Med Sci Monit. 2021 Oct 18;27:e933278.|Microbiome. 2020 Aug 20;8 (1) :120.|Nat Commun. 2024 Jun 10;15 (1) :4947.|Nat Commun. 2024 May 1;15 (1) :3685.|Nat Commun. 2020 Feb 18;11 (1) :941. |Neurochem Int. 2023 Feb:163:105479.|Neuropsychopharmacology. 2024 May 11.|Neurosci Lett. 2021 Aug 24:760:136102.|Psychopharmacology (Berl) . 2022 Mar;239 (3) :951-964.|Viruses. 2021 Aug 3;13 (8) :1533.
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
VK620043-01 50 µg
Anti-Hepatitis E virus/HEV pORF2 P domain Neutralizing Antibody (SAA2240)
Sign In for Pricing
View Details VK620043-02 100 µg
Anti-Hepatitis E virus/HEV pORF2 P domain Neutralizing Antibody (SAA2240)
Sign In for Pricing
View Details VK620043-03 1 mg
Anti-Hepatitis E virus/HEV pORF2 P domain Neutralizing Antibody (SAA2240)
Sign In for Pricing
View Details 
PH303017 10 µg
C1orf57 (NTPCR) (NM_032324) Human Mass Spec Standard
Sign In for Pricing
View Details GTR15351168 1 Vial
Lentiviral human TMEM50A shRNA (UAS) - Lentiviral human TMEM50A shRNA (UAS, GFP) (100)
Sign In for Pricing
View Details